Skip Navigation

Drug-Induced Liver Injury

printer friendly version

Idiosyncratic liver injury associated with drugs (ILIAD)


Enrollment status: OPEN

The goal of the ILIAD protocol is to create a database and bank of biological specimens (DNA, plasma, lymphocytes) from individuals with severe drug-induced liver injury (DILI) due to isoniazid (INH), phenytoin (Dilantin®), amoxicillin/clavulanate (Augmentin®), minocycline, nitrofurantoin, trimethroprim/sulfamethoxazole (Bactrim®), or valproic acid (Depakote®) after January 1, 1994. This study is funded by the NIH/NIDDK.

Study Design

Contacts for referrals or questions: Please see below.

A multicenter, longitudinal study of drug-induced and complementary and alternative medication-induced liver injury


Enrollment Status: OPEN

The goal of this multicenter NIH study is to prospectively identify bona fide cases of liver injury due to drugs and complementary and alternative medications (CAM) within 6 months of onset. Clinical data, blood, DNA, and urine will be collected from affected patients and matched controls for mechanistic and genetic studies.

Study Design


Contacts for referrals or questions for both studies:

Principal Investigator: Robert Fontana, MD –

For more information, see the following web sites:

Drug-Induced Liver Injury Network

NIH funds network to study drug-induced liver injury

NIDDK LiverTox